Caribou Biosciences, Inc.
CRBU
$1.44
-$0.10-6.49%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.50M | 2.40M | 3.94M | 2.20M | 2.67M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.50M | 2.40M | 3.94M | 2.20M | 2.67M |
| Cost of Revenue | 18.94M | 20.61M | 23.82M | 22.40M | 27.69M |
| Gross Profit | -17.44M | -18.21M | -19.87M | -20.20M | -25.03M |
| SG&A Expenses | 7.90M | 8.07M | 8.58M | 9.20M | 10.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.84M | 28.68M | 32.39M | 31.60M | 38.10M |
| Operating Income | -25.34M | -26.28M | -28.45M | -29.40M | -35.43M |
| Income Before Tax | -24.28M | -25.09M | -27.04M | -27.55M | -54.10M |
| Income Tax Expenses | -- | -- | -550.00K | -- | -- |
| Earnings from Continuing Operations | -24.28M | -25.09M | -26.49M | -27.55M | -54.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.28M | -25.09M | -26.49M | -27.55M | -54.10M |
| EBIT | -25.34M | -26.28M | -28.45M | -29.40M | -35.43M |
| EBITDA | -24.71M | -25.63M | -27.77M | -28.77M | -34.26M |
| EPS Basic | -0.24 | -0.26 | -0.28 | -0.30 | -0.58 |
| Normalized Basic EPS | -0.15 | -0.16 | -0.18 | -0.18 | -0.28 |
| EPS Diluted | -0.24 | -0.26 | -0.28 | -0.30 | -0.58 |
| Normalized Diluted EPS | -0.15 | -0.16 | -0.18 | -0.18 | -0.28 |
| Average Basic Shares Outstanding | 100.99M | 95.86M | 94.54M | 93.29M | 93.03M |
| Average Diluted Shares Outstanding | 100.99M | 95.86M | 94.54M | 93.29M | 93.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |